DBV Technologies to Attend EAACI 2024 Congress

DBV Technologies, headquartered in Châtillon, France, has revealed its plans to engage in the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress scheduled from May 31 to June 3, 2024, in Valencia, Spain. The clinical-stage biopharmaceutical company, which is listed on Euronext and Nasdaq, specializes in developing treatments for food allergies and other immunologic conditions with high unmet medical needs.

An important highlight of their participation will be a flash talk presentation by Dr. Nicolette Arends from Erasmus University Rotterdam. Her presentation will delve into data on accidental peanut consumption gathered from DBV's EPITOPE Phase 3 study and its continuing open-label extension study involving peanut-allergic toddlers aged between 1 and 3 years. This presentation aims to shed light on the real-world implications of DBV’s innovative epicutaneous immunotherapy (EPIT) using Viaskin Peanut, which is designed to help reduce the risk of allergic reactions due to accidental peanut exposure.

Daniel Tassé, CEO of DBV Technologies, emphasized the company's dedication to long-term safety and efficacy data collection for Viaskin Peanut in young children. He acknowledged that while avoidance remains the primary defense against allergic reactions, accidental exposure is inevitable, thus highlighting the need for approved treatments to safeguard against such incidents.

Dr. Pharis Mohideen, Chief Medical Officer at DBV Technologies, mentioned that monitoring accidental peanut consumption during clinical studies helps to understand how EPIT with Viaskin Peanut could potentially minimize allergic reactions over time. This insight is crucial for characterizing the clinical benefits of the treatment if it gains regulatory approval.

DBV's symposium at the congress is entitled "Epicutaneous Route: An Innovative Potential Approach to Food Immunotherapy." It will be moderated by Dr. Stefania Arasi, a Pediatric Allergist from Bambino Gesù Children Research Hospital in Rome, and Dr. Philippe Eigenmann, Head of Pediatric Allergy Unit at the Geneva University Hospital. The symposium will feature lectures from Dr. Luciana Tanno of University Hospital of Montpellier, discussing the potential clinical applications of the epicutaneous route, and Dr. Pablo Rodríguez del Río of Hospital Infantil Universitario Niño Jesús, who will present the latest results and future perspectives of using the epicutaneous route in treating peanut allergies.

In addition to the symposium, DBV Technologies will host an exhibit booth (F10) where attendees can learn more about their ongoing clinical trials and the mechanisms of epicutaneous immunotherapy with Viaskin Peanut.

The detailed schedule for the flash talk includes:
- Title: "Reactions Due to Accidental Peanut Consumption During Epicutaneous Immunotherapy for Peanut Allergy in Toddlers"
- Presenter: Dr. Nicolette Arends
- Session: Flash Talks on Pediatrics, FT 15
- Date: Sunday, June 2, 2024
- Time: 8:30 a.m. – 10:30 a.m. CET

A voice recording of the presentation will be accessible on the congress platform, and the poster will be available on DBV Technologies' website post-presentation.

DBV Technologies is committed to transforming the treatment landscape for food allergies, leveraging its proprietary Viaskin™ technology platform. This platform aims to introduce microgram amounts of biologically active compounds to the immune system via intact skin, seeking to desensitize individuals to allergens through epicutaneous immunotherapy (EPIT). Their current focus includes clinical trials for Viaskin Peanut designed for peanut-allergic toddlers and young children.

Operating from Châtillon, with North American operations in Warren, NJ, DBV Technologies' shares are publicly traded on Euronext Paris and Nasdaq. Their research continues to hold promise for millions of individuals living with food allergies, especially young children, as they strive to bring non-invasive, effective treatment options to the market.